Searchable abstracts of presentations at key conferences in endocrinology

ea0004dp32 | Diabetes, metabolism and cardiovascular | SFE2002

Nateglinide effects on the secretion of glycated insulin and glucose tolerance in subjects with Type 2 diabetes

Lindsay J , McKillop A , Mooney M , O'Harte F , Flatt P , Bell P

Aims: Glycated insulin exhibits impaired glucose-lowering ability and increasing evidence supports a role for glycation of insulin in the insulin resistant state of Type 2 diabetes. We used a novel radioimmunoassay to evaluate the effect of the insulin secretagogue nateglinide on plasma glycated insulin in Type 2 diabetes. Methods: Ten patients (5M/5F, age 57.8±1.9 years, HbA1c 7.6±0.5%, fasting plasma glucose 9.4±1.2millimols per litre, creatinine 81.6&pl...

ea0005p273 | Thyroid | BES2003

Conventional withdrawal of thyroid suppression in differentiated thyroid carcinoma: How frequently are adequately raised TSH levels attained?

McLaughlin C , Hunter S , Bell P , McCance D , Sheridan B , Atkinson A

Radioactive iodine scanning and ablative radioactive therapy (RAI) are mainstays of follow-up and therapy in patients with differentiated thyroid carcinoma. TSH levels of 30 or greater are recommended as the levels required for effective use of RAI (see recent British Thyroid Association guidelines).To clarify our own practice we have studied 20 consecutive patients undergoing ablative RAI for thyroid carcinoma (10 papillary, 8 follicular and 2 mixed). The fourteen who had...

ea0003p85 | Diabetes & Metabolism | BES2002

Demonstration of diurnal variation of plasma glycated insulin in type 2 diabetes

Lindsay J , McKillop A , Mooney M , O'Harte F , Bell P , Flatt P

Aims: Increasing evidence supports the role of glycated insulin in the insulin resistant state of type 2 diabetes. We measured 24-hour profiles of plasma glycated insulin, using a novel radioimmunoassay, to evaluate the effects of meal stimulated insulin secretion and the fasting state on production of plasma glycated insulin in type 2 diabetes. Methods: Patients (n=6, HbA1c 7.2±0.6%, fasting plasma glucose 7.4±0.7 mmol l-1, BMI 35.7±3.5 kg m<su...

ea0019p279 | Pituitary | SFEBES2009

Macroprolactinaemia: what is the long-term prognosis? Results from an original series of 55 patients after 10 years clinical follow-up

Wallace I , Satti N , Courtney H , Leslie H , Bell P , Hunter S , McCance D , Sheridan B , Atkinson A

Macroprolactinaemia is defined as hyperprolactinaemia with a predominance of macroprolactin. It is present in approx 15–36% of cases of hyperprolactinaemia. Controversy exists as to the clinical relevance of macroprolactinaemia with a number of short-term studies demonstrating fewer classical symptoms of hyperprolactinaemia. The long-term prognosis is unknown.We have previously reported the findings after 5 years follow-up of a cohort of 55 patients...